<DOC>
	<DOCNO>NCT01974375</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority micafungin dose 100 mg/day versus fluconzeole prevention Invasive Fungal Disease , define accord revise EORTC/MSG criterion , undergo living-donor liver transplantation .</brief_summary>
	<brief_title>Micafungin Versus Fluconazole Prevention Invasive Fungal Disease Living Donor Liver Transplant Recipients</brief_title>
	<detailed_description>This Randomized , Open label , Non-inferiority Study Micafungin versus Fluconazole Korean Prevention Invasive Fungal Disease Living Donor Liver Transplant Recipients After transplant subject randomize one follow treatment arm : - Micafungin 100 mg/day intravenous ( 2.0 mg/kg/day subject weigh &lt; 40 kg ) - Fluconazole 100~200mg/day , IV care oral medication become possible Stratification accord center . Antifungal prophylaxis administer daily period 21 day , hospital discharge , whichever occur first . This open label study ; Study center personnel blind treatment .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Age &gt; 20 year . Undergoing Living Donor Liver Transplantation ( LDLT ) Any systemic antifungal therapy ( exclude fluconazole SDD maximum 7 day ) within 14 day prior randomization . Evidence document ( 'proven ' 'probable ' ) suspect ( 'possible ' ) IFD ( accord EORTC/MSG criterion ) . Allergy , hypersensitivity , serious reaction echinocandin antifungal , study drug excipients . Reimplantation orthotopic transplantation patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Living donor</keyword>
	<keyword>Liver transplant</keyword>
	<keyword>antifungal prevention</keyword>
</DOC>